← Oncology Approval Tracker

FDA DECISION ·

Calquence

acalabrutinib · AstraZeneca

Traditional approvalTraditional conversionMantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As a single agent for adults with mantle cell lymphoma after at least one prior therapy.

LAMPGEN ANALYSIS

Why it matters

FDA converted the previously treated single-agent use from accelerated to traditional approval alongside a distinct first-line combination action.

What research teams should watch

Preserve the two uses as separate eligibility rules, including whether the patient has received any previous therapy.

PRIMARY RECORDS

Sources